Tedor Pharma, a full-service contract development and manufacturing organization (CDMO), has entered into an agreement to provide cGMP contract manufacturing services for Sequential Medicine Ltd.’s triple combination drug product for the short-term treatment of transient insomnia.
 
Sequential Medicine’s product has demonstrated impressive efficacy in early studies, and the company is on track to commence its next clinical trial by the end of this year with supply from Tedor. The selection of Tedor is expected to provide Sequential Medicine with a qualified manufacturing partner for any further developmental requirements and for commercialization upon approval.
 
“We are pleased to be working with Tedor on this important project,” said Tom Dahl, head of product development, Sequential Medicine. “Their capabilities and facilities are a very good match with our company and our program.”
 
Doug Drysdale, president and chief executive officer, Tedor Pharma, said, “We are delighted to partner with Sequential Medicine to provide Phase 2 clinical trial manufacturing services. Our extensive experience in manufacturing combination products makes Tedor well suited to provide both clinical trial supply and mass commercialization.”